Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

ABSTRACT While Epstein-Barr virus (EBV) is the major cause of nasopharyngeal carcinoma (NPC), the value of the humoral immune response to EBV glycoproteins and NPC development remains unclear. Correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NP...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qian-Ying Zhu, Xiang-Wei Kong, Cong Sun, Shang-Hang Xie, Allan Hildesheim, Su-Mei Cao, Mu-Sheng Zeng
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	Epstein-Barr virus nasopharyngeal carcinoma glycoproteins antibody neutralization Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/91799d7a4910481fb5a9b3e80f6abd83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:91799d7a4910481fb5a9b3e80f6abd83
record_format	dspace
spelling	oai:doaj.org-article:91799d7a4910481fb5a9b3e80f6abd832021-11-15T15:31:13ZAssociation between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma10.1128/mSphere.00901-202379-5042https://doaj.org/article/91799d7a4910481fb5a9b3e80f6abd832020-12-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00901-20https://doaj.org/toc/2379-5042ABSTRACT While Epstein-Barr virus (EBV) is the major cause of nasopharyngeal carcinoma (NPC), the value of the humoral immune response to EBV glycoproteins and NPC development remains unclear. Correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC requires systematic study. Here, we applied a cytometry-based method and enzyme-linked immunosorbent assay to measure neutralization of infectivity and antibody response to EBV glycoproteins (gH/gL, gB, gp350, and gp42) of plasma samples from 20 NPC cases and 20 high-risk and 20 low-risk healthy controls nested within a screening cohort in Sihui, southern China. We found that NPC cases have similar plasma neutralizing activity in both B cells and epithelial cells and EBV glycoprotein-specific IgA and IgG antibody levels compared with those of healthy controls. Significant correlations were observed between gH/gL IgG and gB IgG and the neutralizing ability against EBV infection of epithelial cells and B cells. These results indicate that a high level of glycoprotein antibodies may favor protection against primary EBV infection, instead of being low-risk biomarkers for NPC in long-term EBV-infected adults. In conclusion, this study provides novel insights into the humoral immune response to EBV infection and NPC development, providing valuable leads for future research that is important for prevention and treatment of EBV-related diseases. IMPORTANCE Epstein-Barr virus (EBV) is a human oncogenic gammaherpesvirus that infects over 90% of humans in the world and is causally associated with a spectrum of epithelial and B-cell malignancies such as nasopharyngeal carcinoma (NPC). A prophylactic vaccine against EBV is called for, but no approved vaccine is available yet. Therefore, EBV remains a major public health concern. To facilitate novel vaccines and therapeutics for NPC, it is of great importance to explore the impact of humoral immune response to EBV glycoproteins before the development of NPC. Therefore, in this study, we systematically assessed the correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC development. These results provide valuable information that will contribute to designing effective prevention and treatment strategies for EBV-related diseases such as NPC.Qian-Ying ZhuXiang-Wei KongCong SunShang-Hang XieAllan HildesheimSu-Mei CaoMu-Sheng ZengAmerican Society for MicrobiologyarticleEpstein-Barr virusnasopharyngeal carcinomaglycoproteinsantibodyneutralizationMicrobiologyQR1-502ENmSphere, Vol 5, Iss 6 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Epstein-Barr virus nasopharyngeal carcinoma glycoproteins antibody neutralization Microbiology QR1-502
spellingShingle	Epstein-Barr virus nasopharyngeal carcinoma glycoproteins antibody neutralization Microbiology QR1-502 Qian-Ying Zhu Xiang-Wei Kong Cong Sun Shang-Hang Xie Allan Hildesheim Su-Mei Cao Mu-Sheng Zeng Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
description	ABSTRACT While Epstein-Barr virus (EBV) is the major cause of nasopharyngeal carcinoma (NPC), the value of the humoral immune response to EBV glycoproteins and NPC development remains unclear. Correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC requires systematic study. Here, we applied a cytometry-based method and enzyme-linked immunosorbent assay to measure neutralization of infectivity and antibody response to EBV glycoproteins (gH/gL, gB, gp350, and gp42) of plasma samples from 20 NPC cases and 20 high-risk and 20 low-risk healthy controls nested within a screening cohort in Sihui, southern China. We found that NPC cases have similar plasma neutralizing activity in both B cells and epithelial cells and EBV glycoprotein-specific IgA and IgG antibody levels compared with those of healthy controls. Significant correlations were observed between gH/gL IgG and gB IgG and the neutralizing ability against EBV infection of epithelial cells and B cells. These results indicate that a high level of glycoprotein antibodies may favor protection against primary EBV infection, instead of being low-risk biomarkers for NPC in long-term EBV-infected adults. In conclusion, this study provides novel insights into the humoral immune response to EBV infection and NPC development, providing valuable leads for future research that is important for prevention and treatment of EBV-related diseases. IMPORTANCE Epstein-Barr virus (EBV) is a human oncogenic gammaherpesvirus that infects over 90% of humans in the world and is causally associated with a spectrum of epithelial and B-cell malignancies such as nasopharyngeal carcinoma (NPC). A prophylactic vaccine against EBV is called for, but no approved vaccine is available yet. Therefore, EBV remains a major public health concern. To facilitate novel vaccines and therapeutics for NPC, it is of great importance to explore the impact of humoral immune response to EBV glycoproteins before the development of NPC. Therefore, in this study, we systematically assessed the correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC development. These results provide valuable information that will contribute to designing effective prevention and treatment strategies for EBV-related diseases such as NPC.
format	article
author	Qian-Ying Zhu Xiang-Wei Kong Cong Sun Shang-Hang Xie Allan Hildesheim Su-Mei Cao Mu-Sheng Zeng
author_facet	Qian-Ying Zhu Xiang-Wei Kong Cong Sun Shang-Hang Xie Allan Hildesheim Su-Mei Cao Mu-Sheng Zeng
author_sort	Qian-Ying Zhu
title	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
title_short	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
title_full	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
title_fullStr	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
title_full_unstemmed	Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma
title_sort	association between antibody responses to epstein-barr virus glycoproteins, neutralization of infectivity, and the risk of nasopharyngeal carcinoma
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/91799d7a4910481fb5a9b3e80f6abd83
work_keys_str_mv	AT qianyingzhu associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT xiangweikong associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT congsun associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT shanghangxie associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT allanhildesheim associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT sumeicao associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma AT mushengzeng associationbetweenantibodyresponsestoepsteinbarrvirusglycoproteinsneutralizationofinfectivityandtheriskofnasopharyngealcarcinoma
_version_	1718427837234413568

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

Ejemplares similares